2018 Annual Repo rt

Leading the Way to 2030 For nearly three decades, the Hepatitis B Foundation and our research arm, the Baruch S. Blumberg Institute, have been leading the charge to bring hepatitis B outreach, Leading the Way to research and advocacy to the forefront. We have adopted a bold strategy to give a louder voice to this silent epidemic— bringing it into the spotlight to elevate awareness, increase vaccination, screening and linkage to care, accelerate research, and ultimately cure this deadly disease.

Our five-year strategic plan, approved in 2018, is rooted in an 2030 aggressive vision: BY 2030, NO ONE DIES FROM HEPATITIS B. We are confident that a cure for hepatitis B is within our reach, and we are recruiting the best scientists in the field to encourage collaboration, share their progress, and bring a cure to market. We recognize, however, that a cure alone is not enough for our vision. Our plan also includes continuing and expanding our existing programs to emphasize prevention, and provide critical assistance for those managing the disease. Through our Hep B United program, we have set the standard for building coalitions within at-risk communities to provide free awareness, testing, and linkage to care. We have implemented a ground-breaking global initiative in Haimen City, China, that will act as a model as we expand into other highly-affected regions of the world. And we continue to provide information and guidance directly to thousands of people who contact us for help each year. Your commitment to our mission has made all these programs possible, and your continued support will bring us even closer to our vision of a world where hepatitis B is no longer deadly.

Fifty years after its discovery, hepatitis B is still the most common disease in the world. It thrives in silence, but our voices together can make hepatitis B history. We have a clear plan in place to lead hepatitis B into the forefront of scientific advances and public health planning, and eliminate deaths from this virus within our lifetimes. Your continued support has made these advances possible.

The Hepatitis B Foundation and its Baruch S. Blumberg Institute are the nation’s leading nonprofit disease advocacy and research organizations dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. The Hepatitis B Foundation was founded in 1991 and established the Blumberg Institute in 2003 to fulfill its research mission.

2

2018 Annual Report Scientific Research Leading the way to A Cure

through our research arm, the Baruch S. published in Hepatology, providing a consensus Blumberg Institute, we are relentlessly researching statement from leading researchers to identify the promising new innovative treatments for liver cancer most promising areas of focus for hepatitis B and and a cure for hepatitis B. Nearly 50 scientists liver cancer science, and approaches considered work at our Blumberg Institute—one of the largest necessary for a cure. nonprofit groups of researchers investigating hepatitis B, liver cancer, and other liver diseases We expect more of our discoveries, in the world. Our work extends beyond our own and discoveries that we inspire, to reach human laboratories, to the larger hepatitis B research trials soon. Our successes from the past year are community. In 2018, our Roadmap to a Cure was highlighted in this report.

Advancing Hepatitis B and Liver Cancer Research

Keeping a focus on • Found method of • Discovered HBV's Reaching clinical drug discovery and selective killing unusual process of trials the basic science of of hepatocellular producing its “mRNA” carcinoma cells by 4 of our promising findings disease, we have: • Found STING agonist exploiting HBV surface moved into clinical trials as therapeutics for • Identified compounds antigen expressed on in 2018, including two for cancers and chronic with novel activity HCC cells hepatitis B treatment, one viral infectious against HBsAg for cancer treatment and • For use as a new, diseases • Identified new non-invasive marker one for cancer detection • Identified and biomarker to detect of HCC, identified characterized antiviral liver cirrhosis and HBV sequences drug candidate liver cancers integrated adjacent to against yellow fever Reaching the cell oncogenes from • Identified a novel virus, with a new scientific community the urine of people compound, KPD10, mechanism of action with HCC Our Scientists published through our See hepb.org/research 40 peer-reviewed cell-based high- • Identified cellular for more information publications in leading throughput compound proteins that HBV on our research research journals screening, which needs to produce accomplishments. selectively kills HCC cccDNA and to cells expressing HBV repress cccDNA surface antigen expression

3

2018 Annual Report BRINGing LEADERS TOGETHER We provided expert presentations at over 25 national and international conferences

More than 500 We hosted 30 hepatitis B and liver cancer seminars by scientists attended the scientific leaders at 2018 International HBV Baruch S. Blumberg Meeting in Taormina, , Institute coordinated by HBF

Training the researchers of tomorrow

7 Post doctoral Fellows

from universities worldwide

Graduate Medical Junior Undergraduate High School 18 6 3 Research 7 College 25 Students Students Students Fellows Students

from Drexel from Xavier Medical joined our labs to from Drexel, Cornell, trained through our new University, Geisinger School conducted prepare themselves Temple, Penn State educational programs this year Commonwealth research rotations at for careers in science conducted research as part of our commitment to School of Medicine Blumberg and business in our labs tomorrow’s scientists. An exciting and The University of new collaboration with Central trained Bucks School District brought 15 at Blumberg Institute advanced placement chemistry students to the Blumberg Institute every day to conduct real-world research in our labs. Another 10 high school students participated in our celebrated summer program.

4

2018 Annual Report Hepatitis B CAN BE an overwhelming and In 2018, we started confusing diagnosis. Our trained staff answer collecting caller data OUTREACH & from phone consults. PATIENT EDUCATION questions about test results, transmission, vaccinations, and care, and help patients to Our callers asked about: understand what their diagnosis means for their test 35% results health and their future. We guide people with vaccine hepatitis B as they face their diagnosis, and 30% info Leading the way to transmission provide guidance for telling loved ones, finding 17% finding a care, and starting a family. 11% doctor newly 10% diagnosed This year, we educated patients, family members, BETTER HEALTH possible employers and health officials through: 10% exposure   9,953 1.8 million 12 consultations visits to our website, Updated website via phone, email, and representing chapters in social media over 200 countries 12 languages

National Storytelling Campaign Shines a Spotlight on Hepatitis B

There is no better way to raise public understanding about the true impact of hepatitis B than through personal stories. In 2017, the Hepatitis B Foundation unveiled its #justB national storytelling campaign with real people sharing their stories about hepatitis B. This national storybank is designed to put a human face on hepatitis B in order to increase public awareness, decrease stigma and discrimination, and to promote testing and treatment, which will ultimately save lives.

Forty storytellers share their experiences with hepatitis B and liver cancer both online, and at in-person educational events throughout the U.S. Over 2.2 million people have viewed our stories, improving awareness around the world. You can watch all our #justB stories at www.hepb.org/justb.

Connecting Patients with our Programs

In addition to hepatitis B outreach, we also offer programs to provide support and information for conditions that impact people with hepatitis B:

Hepatitis Delta Connect aims to increase awareness and education about this deadliest form of viral hepatitis, which only infects those with hepatitis B. Information is available in 3 languages, and we have connected with 500 individuals for consults, and reached 3,000 people through our educational webinars. Visit www.hepDconnect.org.

Liver Cancer Connect works to educate those at risk for liver cancer and provides support through its email helpline and social media channels for patients and families. Visit www.livercancerconnect.org.

5

2018 Annual Report Public Health To reach our goal of reducing deaths from hepatitis B, the Hepatitis B Foundation issued a formal recommendation this year that all Americans be tested Leading the way to for hepatitis B. To bring the disease to the forefront, we must be aggressive in our efforts to test, vaccinate, treat, and prevent the spread of hepatitis B. But we can’t stop Eliminating there. We will continue to build new coalitions, and support existing efforts to ensure that every infected person knows their status and has access to care that can Hepatitis B save their life.

Hep B United

Hep B United, a national coalition Hep B United brought over 80 of our coalition In 2018, Hep B United established by HBF in partnership with the partners together for its 6th Annual National Philadelphia educated Association of Asian Pacific Community Summit to advance our movement to address over 2,000 people, Health Organizations, has demonstrated and eliminate hepatitis B. The Hepatitis B screened 150, and great success in bringing community leaders, Foundation also facilitates our local coalition, linked 90% of infected providers, medical and public health students, Hep B United Philadelphia (HBUP), which individuals to care. We and state and local health departments serves a vital role as a mentor for newly-formed also hosted professional together with at-risk communities. Hep B coalitions in other cities, and as a testing trainings for over 150 United added 4 new partners this year ground for new programs. clinicians and public bringing our reach to 30 cities in 21 states. health partners. Increasing awareness, screening, vaccination and linkage to care

21 States

30 Cities

6

2018 Annual Report Hep B United Summit brought over 80 of our hepatitis B coalition partners together for HBU’s 6th Annual Summit to advance our movement to address and eliminate hepatitis B.

Coalition Against Hepatitis in People of African Origin

HBF leads the national Coalition Against Hepatitis in People of African Origin (CHIPO), a community coalition of organizations to address the high rates of hepatitis B infection among African communities in the U.S. This year, our work included a collaboration with the Centers for Disease Control and Prevention (CDC) to create a broad scale educational initiative to promote hepatitis B awareness and testing for African immigrants across the . This exciting project is the first of its kind to provide targeted educational materials to often-overlooked African immigrant communities.

International Reach

Since 2011, the Hepatitis B Foundation has sponsored an ambitious public health campaign in Haimen City, China to reach all 1 million residents with information about hepatitis B. Building on our success in China, we have partnered with organizations to help them bring hepatitis B awareness, testing and care in Ho-Chi Minh, Vietnam and Accra, Ghana.

7

2018 Annual Report 2017 Annual Report Advocacy Leading the way by Taking Action

Through our efforts, the hepatitis B voice has grown steadily louder in Washington, DC. As the recognized authority on the fight against hepatitis B, The Hepatitis B Foundation has led the charge to bring government attention and funding to the epidemic of viral hepatitis. We have also worked to fight persistent discrimination that people with hepatitis B face as they apply to work, go to school, enlist in the military, and seek healthcare.

8

2018 Annual Report Hep B Cure Campaign

Hepatitis B has long been underfunded in contrast to government spending on similar epidemics. The Hepatitis B Foundation has focused our efforts on a major advocacy campaign, the Hep B Cure Campaign, aimed to double federal spending on hepatitis B. Our Cure Campaign has already seen success with publication of our Roadmap for a Cure, which identifies areas of promising research and funding. We are working to continue our efforts to increase funding for research by $39 million a year for the next six years, and are advocating for better coordination of research through the National Institutes of Health.

Hep B United Advocacy Day Bring the Message to Washington

During the Hep B United Advocacy Day, nearly 70 advocates met with more than 60 Congressional offices to discuss increasing federal resources to address and eliminate hepatitis B and liver cancer. We also now reach over 430 people through our online grassroots advocacy network, at hepbunited.org.

FIGHTIng DISCRIMINATION IN THE U.S. Fighting Discrimination in the U.S.

The Hepatitis B Foundation is working tirelessly to end the stigma and ensure that people with hepatitis B are afforded the same opportunities as everyone else. Our advocacy successfully made hepatitis B a protected condition under the Americans with Disabilities Act (ADA) in the United States, and we continue to fight to ensure that people receive those protections. In addition to ensuring that medical schools and employers comply with ADA protections, we are also fighting for fair access to medicines. Learn more about our work at hepb.org/rights.

9

2018 Annual Report Our Vision Leading the way to a World Where No One Dies of Hepatitis B

The Hepatitis B Foundation is committed to a future without hepatitis B, and we have a plan to get there. In 2018, we adopted an ambitious five-year plan based around the vision that by 2030, no one dies of hepatitis B. Our Roadmap to Cure provides a blueprint for the research necessary to bring better treatments and a cure, and our public health priorities support the education, awareness and infrastructure needed to stop the spread of the virus.

Achieving our vision will require a global focus to expand our resources and capabilities across the world in order to »

10

2018 Annual Report Create a Patient Voice Our presence in communities of high prevalence must increase. Education, awareness, and advocacy on behalf of individuals fighting discrimination and stigma is underway, but we know there are many more cases of people suffering from workplace, military, and educational access discrimination. Working with our coalition of partners across the country, we can help them scale up efforts in over 20 states.

Improve International Capacity Internationally, resources are scattered and uncoordinated. But the Hepatitis B Foundation is poised, as the global leader in this space, to take on the challenge and build an international coalition similar to the United States Hep B United model, resulting in “Hep B United Global” or “HBUG”. This will lay the groundwork for projects in 5 different countries around the globe to save millions of lives.

Foster discovery of a cure for hepatitis B We need to give the scientists of the Baruch S. Blumberg Institute the tools to conduct cutting edge research. Vision, commitment and patience is required to accelerate the pace toward a “functional” cure, which we believe exists somewhere within the new wave of HBV therapeutics.

11

2018 Annual Report Thank You to Our Donors

The Hepatitis B Foundation’s valuable research and programs are made possible by the commitment of our donors. We are grateful to every individual and organization that has generously supported our mission to find a cure and improve the quality of life for those affected by hepatitis B. Our Donor Honor Roll January - December 2018

Visionary Circle Global Circle Founder’s CIRCLE ($10,000 and above) ($5,000 to $9,999) ($2,500 to $4,999) Anonymous Alnylam US, Inc. Nathaniel Brown Arbutus Biopharma Arrowhead Pharmaceuticals Inc. Bonnie Chang & Robert Hsu Timothy & Joan M. Block Assembly Biosciences, Inc. EisnerAmper LLP Carol and Edmund Blake Foundation Bristol-Myers Squibb Anthony & Jane Ford-Hutchinson Dynavax Alan & Patty Brownstein Herman Goldman Foundation Eiger Biopharmaceuticals, Inc. CTC Foundation High Swartz LLP Fred Beans Family of Dealerships Linda London KMT Hepatech Inc. Gilead Sciences, Inc. Merck & Co. Faye & Mayer Krupp Family Kahn Charitable Foundation, Penn Community Bank Charitable Foundation Shannon Wu & Joseph Kahn Softerware Inc. Lion TCR Prevent Cancer Foundation Priscilla Tennant Bruce & Cynthia Maryanoff Quest Diagnostics Paula Wong & W. Robert Magee, Jr. Norwood Company RFS Family Foundation, Joel Rosen Raymond Schinazi Worldwide Life Sciences Roche-Genentech Spring Bank Pharma Univest Corporation of PA Catharine & Rob Williams

President’s Club Geisinger Commonwealth Penn Color, Inc. ($1,000 to $2,499) School of Medicine Yusheng Qu Abbott Laboratories Gilmore & Associates Inc. Richman Chemical Inc. ADMA Biologics, Inc. Glycotest Spark Nonprofit Consulting LLC Jon Biedermann Adam Grossman Stark & Stark Blank Rome LLP David & Cynthia Gruber Tulchin Family Foundation Stanley & Gerri Broadbent Anne Heacock Nagachaitanya Vellanki Carol Brosgart Ram Kapur Michael Wehner Bob & Joyce Byers Kevin Kruse Wojdak Government Relations Richard & Flo Celender Lafayette Ambassador Bank Worth & Company, Inc. Gang Chen Patrick Lam Wayne Yetter Moon Chen Arthur & Nancy Laskin Tianlun & Amy Zhou Chari & Paul Cohen James Laskin Steve & Janet Cohen Limbach Co. LLC Thomas Shenk & Lillian Chiang Mary Anne McDonald & Joseph Benning Molli & Joe Conti Richard Moyer David Family Charitable Foundation Network for Good Craig & Janet Esterly Anna O'Connell Fisher Scientific Timothy Ocain Fulton Bank Premier Division OrthogenRx, Inc.

12

2018 Annual Report Patrons ($500 to $999) IteraMed Consulting LLC Peter Leone Matthew & Wendy Adlai-gail JBS Science, Inc. Edward Lin Anonymous Joanne Jensen Michael Line Clement Au Margaret Keenan Amy Liu Eileen Beck Robert Kelley Dapeng Liu Bee Bergvall & Co. Peter Lamberts Jessica Lorenz Terri Chen Jennifer Maher Kenneth Lu Conifer Point Pharmaceuticals Brian McMahon Emily Mao McCarty CP Commercial Printing Loujan Mourad Jennifer Miller William Delaney Moyer Indoor Outdoor James & Barbara Mongold Demusz Brothers, Inc. PNC Wealth Management Catherine Morris & Donation Line, LLC Kenneth & Maria Rothstein Richard Bader Yanming Du Guiseppe Sarrica Markus Musa Greene Street Pharmaceuticals Caroline Satchell Meredyth Nash Maureen Kamischke Christoph & Mirjam Seeger Deigo Mora Navarro Louis & Jeannie Kassa Susan Stellini Richard & Teresa O'Flynn Kathleen Kerrigan Tescor Inc. John Oldani Anna Lee Walter Tsou Anthony Oppenheim & Lewis and Rosebud Roberts Family Fund Dennis Wen Cathy Block Madison Associates, LLC Woodmansee & Co. Val Orekhov Michele Nasti George and Cathleen Woods Linda Park Debora Nelson Anchi Wu Steve Pelland Rasna Therapeutics Mary Yee Janet Perper Lewis Roberts Cheng Zeng Rupali Praveen Samuel P. Mandell Foundation Paul Raetsch Daniel and Lena Solaiman James & Kathleen Ryan Michael & Charleen Sofia Supporters ($100 to $249) Jasmin Sabado Leaf Sternberg Ishola Adeyemo Ronald & Joyce Sanderson Lishan Su Ovidiu Aldea Y. Clement Shek Ying-Hsiu Su & Wei Song Laurie & James Beckert Toby Sherwood Tiziana Life Sciences Susan Bellaire & John Massey Jim & Kathleen Shryock Jeane Vidoni Sandra Bendt Thomas & Harriet Stenzel A. Rhodes Wilson Joanne Blasenheim Sterotherapeutics, LLC Paul & Jan Witte Jennifer Boardman Linhui Sui Bill & Mary Kell Cayley David Sul Everett & Diana Chambers Susan Sun Fellows ($250 to $499) Garrett Chang James Talamonti Leo Adalbert Cong Cheng Judy Tam Ark Pharm David & Kathleen Christenson Gary Triozzi Blooming Minds Design, LLC Margaret Copeland Philip & Philippa Wharton Gregory and Susan Braithwaite Andy Cuconati Roy Williams Anthony Cha Zebene Deresse Shari & Steve Winkler Daniel Chan Mary Cushing Doherty Stephen Wong Jinhong Chang William Donaldson Onanong Wongwichai Joly Chang Mike Dugery Kechang Wu & Yuling Lo Feng Chen Exude, Inc. Yalin Xiong Del Val Power and Light, Inc. Theodore Feldstein Shihyun You Sejong Ding Kurt & Janet Ferguson Marissa Yu John Ellis Edward Fischer Thomas Zipp Karl Emerson KT Foundation Brian C Eves, Esq. Brian Free Lalo Flores Lawrence Friedman & Friends (Up to $99) Daniel & Jamie Fox Mary Jo Cappuccilli Joann Albert & Daniel Green Fox Chase Chemical Diversity Center Curt & Rosanne Friehs V. Alexiades Alan Freedman Edan Gal Kyle Anderson Anne Frey Michelle Gerber Priyanka Banerjee Frontier Scientific Joseph Gonnella Patricia Benham Roger & Nancy Gallic William Green Janet Bergstrom Graphic Edge, Inc. Hunt Hawkins & Elaine Smith Kamlesh Bhagnani Richard Grillo David Hines Steven Bingham & Jack Leonard Ronyi Gu Peter Hoekstra Steve Black Ju-Tao Guo Max Holt Geraldine Block Hie-Won Hann Kenny Hom Ron & Debbie Blough Franklin & Carol Hart Yuko Hwang Stephen Borowski Virginia Heatwole Julie Jacob Elaine Brennan Jean Holmes & Lisa Mathason Jeffrey Jacobson Robert Britt Eva Honsa-Hogg Amy Jessop Nelson Campbell ImmunoRestoration, Inc. Donald & Kimberly Jungkind Paolo Cecchetti InterLink Karen Lassman-Eul Ka-Ming Chan

13

2018 Annual Report Manju Chatani Judith Marchand Hepatitis B Foundation Li-Heng Chen Kerry Marshall Legacy Society Rachel Cheng James Massie & Janice Scott Recognizing donors who have Ksheerasagar Chintalapalli Jim McGowan included HBF in their wills or Stephen Chow Lynne Mercedes made a planned gift William & Rita Clark Tulin Morcol Timothy and Joan Block Robert Cohoon Xiaohong hu Mueller Craig and Janet Esterly Joan Copp Pallavi Nimkar Jean Miller Raymond D'Auria Jason Nunez C. Theodore Tucker Daniel DiMaria Jeanne Oesch Catharine and Rob Williams Sheryl Dominguez Emily Oppenheim Paul and Janine Witte Ronald Drakeford Meg & Michael Ovitt John & Sandy Draus John Perez Donna Dunham Edward Peritz Matching Gift Programs James Dzikowski Ted Popper Amazon Smile Foundation ECHO of Northrop Grumman Polly Ranson America's Charities EFB, Inc. Franchise of Uno Anna Ridout Amgen Foundation Matching Gift Program John Estok William Ryle AT&T United Way Employee Giving Campaign Glenn Galang Nick Sasomsub Bank of America Employee Giving Campaign Richard Garza M Rafi Shaik Benevity Community Impact Fund David Gaskin Myong Shin Give with Liberty Campaign Gabriel Gavrilescu Musa Shodunke IBM Employee Services Center Sudhanva Gnaneshwar Ping Shyr JP Morgan Chase Employee Giving Rylan Goudreau Priscilla Smith Merck Partnership for Giving Renee Haliburton Denise Stern Nvidia Employee Giving Program Deborah L. Hennel Ray Tai Pledgeling Foundation Xiaoling Hong Lance Than United Way California Capital Region Nhi Hua Robert Thran United Way of the Bay Area Paing Huang Patricia Trainor YourCause, LLC Shabbir Husain Albert Tsai Jane Johnston Harry C. Tse Suzanne Kahn Hin Tse Christie Kan Heng FU Tseng Thank you Nina & Paul Katz Charles Wagner to our many In-Kind Donors who Jenny Kimbel Carrie Welch & Sherman Labarge are too numerous to mention. Mariemel Latorre Vanessa Wenzell ...... Abraham Leibson & Sharon Victor Helen Wise Michelle Levesque Adelynn Woodard King & Ying Liang Jay Wrobel Neil Liu Laura Young Hoang Ma Xinxian Zhang Maria Macwilliams Leo Zheng Paul Man Mei Zheng

We apologize in advance for any errors or omissions in our Donor List despite our best efforts to be as accurate as possible. Please email [email protected] or call (215) 489-4900 so that we can print corrections in our next newsletter. Thank you for understanding.

14

2018 Annual Report Year In Review + Financial Information* COmbined Hepatitis B Foundation & Baruch S. Blumberg Institute** For the fiscal year ended June 30, 2018

68% Grants ($6,208,754) 8% Charitable contributions ($713,007) 6% Natural Products Institute ($548,979) Source 5% Management fees ($445,550) 1% Special events ($89,200) of Funds 5% Research Meeting ($413,819) 7% Other revenue ($658,945) 1% Investment income ($108,536) TOTAL REVENUE $9,186,790

65% Research ($5,659,219) 5% Outreach and Education ($446,049) USe 19% General and Administrative ($1,694,637) of Funds 1% Development ($65,780) <1% Affiliation Charges ($22,420) 10% Rent and Depreciation ($843,841) TOTAL EXPENSE $8,731,946

* The financial information presented above does not include the activity from Hepatitis B Foundation's ownership of the net assets of the Pennsylvania Center. At June 30, 2018, this interest was valued at, based on the equity method of accounting, approximately $4,959,000 per the audited Statement of Financial Position of the Hepatitis B Foundation. ** The financial information presented above excludes unrealized investment related activities. *** Excludes in-kind donations **** Baruch S. Blumberg Institute is the reseach institute established by the Hepatitis B Foundation in 2004 The financial information in this report was prepared by management and presented in condensed form from the financial statements of the Hepatitis B Foundation and the Baruch S. Blumberg Institute audited by EisnerAmper, LLP for the year ended June 30, 2018. A copy of each financial statement is available upon request.

15

2018 Annual Report The Hepatitis B Foundation and its Baruch S. Blumberg Institute are the nation’s leading nonprofit research and disease advocacy organizations dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. The Hepatitis B Foundation was founded in 1991, and established the Baruch S. Blumberg Institute in 2003 to fulfill its research mission.

HBF BOARD OF DIRECTORS In Memoriam: Baruch S. Blumberg, MD, DPhil Chairman Nobel Laureate Joel Rosen, Esq. W. Thomas London, MD President Bud Tennant, DVM BARUCH S. BLUMBERG Timothy M. Block, PhD INSTITUTE BOARD OF Medical Director Vice President DIRECTORS & OFFICERs Robert Gish, MD Catharine Williams, MGA Chairman Special Advisors Treasurer Wayne Yetter Bob Bowman, PhD Joseph Hediger President Gang Chen, MD, PhD Timothy M. Block, PhD Secretary Eddie Cheung, MD Wayne Yetter Nadine Shiroma Treasurer Stanley Broadbent Joseph Hediger Carol Brosgart, MD STAFF Secretary Nathaniel Brown, MD President Louis P. Kassa, MPA (non-voting) Alan Brownstein, MPH Timothy M. Block, PhD Loren Danzis, Esq. Loren Danzis, Esq. Executive Vice President/ Joel Rosen, Esq. Craig Esterly Chief Operating Officer Thomas Shenk, PhD Anthony Ford-Hutchinson, PhD Louis P. Kassa, III, MPA Michael Sofia, PhD (non-voting) David Gruber, CPA Senior Vice President Raman Kapur, MBA Hepatitis B Foundation Thomas Shenk, PhD Chari Cohen, DrPH, MPH and Baruch S. Blumberg Walter Tsou, MD Vice President, Research Institute Faculty Su Wang, MD, MPH Ju-Tao Guo, MD Timothy M. Block, PhD On-site Adjunct Faculty Medical and Scientific Advisors Vice President, Jinhong Chang, MD, PhD Dennis Gross, MBA, PhD Harvey Alter, MD Institutional Advancement Jason Clement, PhD Nikhil Heble, JD, PharmD Timothy M. Block, PhD Jean Holmes, MBA Chari Cohen, DrPh, MPH David Horn, MD Yanming Du, PhD William Kinney, PhD Carol Brosgart, MD Outreach and Public Health Catherine Freeland, MPH Cynthia Maryanoff, PhD Nathaniel Brown, MD Catherine Freeland, MPH Ju-Tao Guo, MD Raj Patil, PhD Francis Chisari, MD Michaela Jackson, MS Xuanmao Jiao, PhD Patrick Romano, PhD Raymond Dwek, D. Phil, FRS Maureen Kamischke John Kulp, PhD Michael Sofia, PhD Anthony Ford-Hutchinson, PhD Kate Moraras, MPH Patrick Lam, PhD Lawrence Friedman, MD Sierra Pellechio, CHES Off-site Adjunct Faculty Zhiping Li, PhD Don Ganem, MD Rhea Racho, MPAff Gang Chen, MD, PhD Robert Gish, MD Bruce Maryanoff, PhD Andrea Cuconati, PhD Institutional Advancement Hie-Won L. Hann, MD Sung Park, PhD Doan Dao, MD, PhD Jenny Kimbel Stephen Locarnini, MD, PhD Richard Pestell, MBA, MD, PhD Richard Davidson, PhD Susanna McGrogan Anna Lok, MD Aejaz Sayeed, PhD Alison Evans, ScD Megan Pierce William Mason, PhD Kunwar Shailubhai, PhD, MBA Nicholas Meanwell, PhD Brian McMahon, MD Finance and Operations Ying-Hsiu Su, PhD Chris Moore, PhD Edith Mitchell, MD Deborah Blough Roshan Thapa, MD Robert P. Perillo, MD, FAASLD Chris Cheshire Matthew Todd, PhD Lewis Roberts, MB, ChB, PhD Nicole Grasso Tianlun Zhou, MD, PhD, MPH Kenneth Rothstein, MD Mark Hansen Teaching & Lab Faculty Raymond Schinazi, PhD Konrad Kroszner Sahithi Pamarthy, PhD Thomas Shenk, PhD Judith Marchand Darl Swartz, PhD John Tavis, PhD Patti McAloon, MBA Wei Xie, PhD Dianna Miller Board Members Emeritus Fanny Zhang, PhD Loretta Molle Joan M. Block, RN, BSN Ray Savage Janine Witte

Join Our Global Conversation

/hepbfoundation @hepbfoundation @hepbfoundation

/hepbfoundation hepb.org/blog @hepbfoundation

3805 Old Easton Road, Doylestown, PA 18902 Phone: (215) 489-4900 Fax: (215) 489-4920 Email: [email protected] Visit www.hepb.org and www.blumberginstitute.org